Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

被引：0

作者：

Fisher, Benjamin A. ^{[1
]}

Mariette, Xavier ^{[2
]}

Papas, Athena S. ^{[3
]}

Grader-Beck, Thomas ^{[4
]}

Bootsma, Hendrika ^{[5
]}

Ng, Wan-Fai ^{[6
]}

Van Daele, Paul ^{[7
]}

Finzel, Stephanie ^{[8
]}

Elgueta, Sergio ^{[9
]}

Hermann, Josef ^{[10
]}

McCoy, Sara ^{[11
]}

Bookman, Arthur ^{[12
]}

Sopala, Monika ^{[13
]}

Luo, Wen-Lin ^{[14
]}

Scheurer, Cornelia ^{[13
]}

Hueber, Wolfgang ^{[13
]}

机构：

[1] Univ Birmingham, Birmingham, W Midlands, England

[2] Univ Paris Saclay, Le Kremlin Bicetre, France

[3] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA

[4] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA

[5] Univ Med Ctr Groningen, Dept Rheumatol, Groningen, Netherlands

[6] Newcastle Tyne Hosp NHS Fdn Trust, NIHR Newcastle Clin Res Facil, Newcastle Upon Tyne, Tyne & Wear, England

[7] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands

[8] Univ Freiburg, Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany

[9] Clin Res Chile SpA, Biomed Res Ctr, Valdivia, Chile

[10] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, Graz, Austria

[11] Univ Wisconsin, Sch Med & Publ Hlth, Middleton, WI USA

[12] Toronto Western Hosp, Toronto, ON, Canada

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Pharmaceut, E Hanover, NJ USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1634

引用

页码：3242 / 3244

页数：3

共 50 条

[31] Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial
D'Haens, Geert R.
Panaccione, Remo
Higgins, Peter
Colombel, Jean-Frederic
Feagan, Brian G.
Moscariello, Michele
Chan, Gary
Healey, Paul J.
Niezychowski, Wojciech
Wang, Wenjin
Marren, Amy
Maller, Eric
GASTROENTEROLOGY, 2016, 150 (04) : S183 - S183
[32] EFFICACY OF NISOLDIPINE IN STABLE ANGINA - RESULTS OF A MULTICENTER, PLACEBO-CONTROLLED DOSE-RANGING AND RANDOMIZED DOUBLE-BLIND-STUDY
DIBIANCO, R
GLASSER, SP
SMITH, V
THADANI, U
CIRCULATION, 1985, 72 (04) : 275 - 275
[33] Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
van der Heijde, Desiree
Deodhar, Atul
Wei, James C.
Drescher, Edit
Fleishaker, Dona
Hendrikx, Thijs
Li, David
Menon, Sujatha
Kanik, Keith S.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1340 - 1347
[34] Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Thaci, Diamant
Simpson, Eric L.
Beck, Lisa A.
Bieber, Thomas
Blauvelt, Andrew
Papp, Kim
Soong, Weily
Worm, Margitta
Szepietowski, Jacek C.
Sofen, Howard
Kawashima, Makoto
Wu, Richard
Weinstein, Steven P.
Graham, Neil M. H.
Pirozzi, Gianluca
Teper, Ariel
Sutherland, E. Rand
Mastey, Vera
Stahl, Neil
Yancopoulos, George D.
Ardeleanu, Marius
LANCET, 2016, 387 (10013): : 40 - 52
[35] Efficacy and safety of etrasimod in Japanese UC patients: results of a phase 2 dose-ranging study
Takeuchi, K.
Nakase, H.
Hisamatsu, T.
Matsuoka, K.
Arai, S.
Yuasa, H.
Oe, M.
Ono, R.
Keating, M.
Gu, G.
Lazin, K.
Mcdonnell, A.
Fokuta, K.
Hibi, T.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1183 - i1185
[36] A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
Sands, B.
Sandborn, W.
Feagan, B. G.
Lichtenstein, G.
Zhang, H.
Szapary, P.
Panes, J.
Vermeire, S.
O'Brien, C.
Dewey, J.
Yang, Z.
Johanns, J.
Strauss, R.
Marano, C.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S71 - S72
[37] A Phase 2B, Multicenter, Randomized, Placebo-Controlled Dose-Ranging Trial of Peficitinib, an Oral JAK Inhibitor, in Patients with Moderately-Severely Active UC
Sands, Bruce
Sandborn, William
Feagan, Brian
Lichtenstein, Gary
Zhang, Hongyan
Szapary, Philippe
Panes, Julian
Vermeire, Severine
Christopher, O. O'' Brien
Dewey, Julia
Yang, Zijiang
Johanns, Jewel
Strauss, Richard
Marano, Colleen
INFLAMMATORY BOWEL DISEASES, 2017, 23 : S8 - S8
[38] EFFICACY AND SAFETY OF CNTX-4975 IN SUBJECTS WITH MODERATE TO SEVERE OSTEOARTHRITIS KNEE PAIN: 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
Stevens, R.
Petersen, D.
Ervin, J.
Nezzer, J.
Nieves, Y.
Campbell, J.
Guedes, K.
Burges, R.
Hanson, P.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 121 - 121
[39] Efficacy and Safety of Cntx-4975 in Subjects with Moderate to Severe Osteoarthritis Knee Pain: 24-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Stevens, Randall
Petersen, Dena
Ervin, John
Nezzer, Jennifer
Nieves, Yeni
Campbell, James
Guedes, Kimberly
Burges, Robin
Hanson, Peter
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[40] Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
Peter V. Dicpinigaitis
Alyn H. Morice
Jaclyn A. Smith
Mandel R. Sher
Michael Vaezi
Laurent Guilleminault
Akio Niimi
Kerstin Gude
Ulrike Krahn
Riitta Saarinen
Philippe Vieira Pires
Melanie Wosnitza
Lorcan McGarvey
Lung, 2023, 201 : 255 - 266

← 1 2 3 4 5 →